Singapore markets open in 6 hours 21 minutes
Straits Times Index
3,290.70 +24.75 (+0.76%) S&P 500
5,222.68 +8.60 (+0.16%) Dow
39,512.84 +125.04 (+0.32%) Nasdaq
16,340.87 -5.43 (-0.03%) Bitcoin USD
61,424.21 +237.30 (+0.39%) CMC Crypto 200
1,270.64 -87.37 (-6.43%)
REGN Jan 2025 710.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:52AM EDT. Market open.
Loading interactive chart…
- Simply Wall St.
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
Key Insights Institutions' substantial holdings in Regeneron Pharmaceuticals implies that they have significant...
- Thomson Reuters StreetEvents
Q1 2024 Intellia Therapeutics Inc Earnings Call
Q1 2024 Intellia Therapeutics Inc Earnings Call
- GlobeNewswire
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is currently enrolling infants and children in the U.S., UK and Spain TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) wi
© 2024 Yahoo. All rights reserved.